Incretin biology: connecting the gut, glucose, and clinical research

The incretin effect shows that the route by which glucose enters the body changes the insulin response. Understanding this physiology helps interpret GLP-1 and GIP research without treating all receptor agonists as interchangeable.

Demonstrating the incretin effect

The incretin effect is studied by comparing oral glucose with an intravenous infusion that produces a similar blood glucose level. The insulin response is usually greater after oral administration in healthy individuals. This difference suggests the involvement of gut-related signals. The comparison requires comparable blood glucose levels, not simply equal amounts of glucose administered. If this control is lacking, part of the difference could be explained by the glycemic stimulus. The experiment allows for the isolation of one physiological contribution. It does not, on its own, identify all the mechanisms of a treatment. Showing two pathways without explaining blood glucose control would leave the argument supporting the incretin effect incomplete.

GLP-1 and GIP

The two main mediators are GLP-1 and GIP. Their names correspond to peptides released by enteroendocrine cells in response to nutrients. Both participate in the regulation of insulin secretion, although they do not have identical actions. Their receptors and effects must be studied separately. To understand the system, avoid treating them as two names for the same hormone. It is also important to distinguish between secretion, circulating concentration, and tissue response. A similar concentration does not guarantee an equivalent response. This distinction will help in understanding the differences observed in diabetes.

Glucose dependence

The insulinotropic action of incretins depends on the glycemic context. This means that the stimulus for insulin secretion changes with glucose availability. This is a relevant physiological characteristic, but it does not equate to the absolute absence of hypoglycemia during any treatment. Other medications and patient conditions can modify the risk. For example, combination therapy with insulin requires its own evaluation. Nor should we assume that all actions of the incretin system share this exact dependence. To reason precisely, specify which response you are describing. Talking about insulin secretion is more accurate than attributing a single property to all the effects of an entire hormonal and pharmacological family.

Actions beyond insulin

GLP-1 participates in several metabolic responses. In addition to promoting insulin secretion, it is involved in glucagon regulation and food intake pathways. It can also modify gastric emptying. The magnitude and persistence of each effect depend on the context and the intervention. Therefore, it would be incomplete to explain weight loss solely as delayed gastric emptying. Trials determine what results are obtained with a molecule, a regimen, and a population. Maintaining this distinction prevents the physiological explanation from promising more than it has demonstrated.

Signal degradation

Active endogenous incretins have limited persistence due to degradation and elimination processes. One relevant enzyme is DPP-4. This knowledge has allowed for the development of different pharmacological strategies. One aims to prolong the endogenous signal by inhibiting the enzyme. Another uses agonists designed to activate receptors with distinct exposure profiles. These strategies are not equivalent, nor do they necessarily produce the same magnitude of effect. The shared mechanism of origin does not eliminate clinical differences. To interpret a comparison, identify which intervention each group received. Then review outcomes and conditions. Understanding degradation explains part of the drug design, but it does not allow for substituting one class for another without appropriate clinical evidence.

The incretin effect in diabetes

In type 2 diabetes, a reduction in the incretin effect has been described. This does not imply an absence of incretin secretion or an identical impairment of GLP-1 and GIP responses. Physiological studies have found differences in the response to GLP-1 and GIP. These observations depend on the population and the experiment. It is not appropriate to summarize them by stating that a receptor is permanently switched off. Subsequent pharmacology demonstrates that the system allows for more complex interventions. To understand this, keep in mind the difference between endogenous hormone, experimental administration, and therapeutic agonist. Each generates a distinct exposure. Pathophysiology guides development, but it does not, on its own, predict all the outcomes of medications.

From physiology to a studied treatment

Therapeutic development transforms a physiological finding into a concrete intervention. Semaglutide and tirzepatide illustrate different strategies within this process. The former acts as an agonist of the GLP-1 receptor. The latter combines agonism of both GIP and GLP-1. Their clinical outcomes cannot be inferred solely from these names. Exposure, tolerability, and outcomes must be evaluated through studies. Nor does an endogenous hormone guarantee unlimited safety for an analogue. The concentration, duration, and target population may differ. This connects to the previous module. Pharmacodynamics and pharmacokinetics explain possibilities; clinical trials establish the scope of therapeutic conclusions.

What to remember

Identify the actual molecule, population, comparator, and endpoint in every clinical claim. A physiological pathway explains a research rationale; trials determine what a particular intervention achieved.

Continue with PEPTIDE Academy, Module 3. The complete lessons remain in the Academy; this public article introduces selected concepts.

Related reading: weight and joint pain

The STEP 9 reading card adds a joint-pain example alongside STEP 1. Symptom improvement is a different claim from cartilage regeneration.

Lean mass and function

Related draft: BELIEVE and interpretation of body-composition research.

Other clinical research questions

The alcohol-use reading card distinguishes outcomes that changed from those that did not in an early trial.

Related readings: STEP 9: weight, knee pain and function, BELIEVE: body composition is not the same as function, Semaglutide and alcohol: an early randomized trial.